trazodone has been researched along with Idiopathic Parkinson Disease in 5 studies
Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To test the ability of a 5HT2a/c (trazodone) antagonist, to improve depression and motor function in Parkinson' disease (PD)." | 5.14 | The use of an antagonist 5-HT2a/c for depression and motor function in Parkinson' disease. ( Rosso, AL; Vincent, MB; Werneck, AL, 2009) |
| "Melatonin intake was associated with a higher decrease in RBDSQ score compared to trazodone (P = 0." | 3.11 | Safety and efficacy of melatonin, clonazepam, and trazodone in patients with Parkinson's disease and sleep disorders: a randomized, double-blind trial. ( Agah, E; Aghamollaii, V; Hadi, F; Mirsepassi, Z; Mousavi, SV; Tafakhori, A; Talachi, N; Tavanbakhsh, S, 2022) |
| " Following oral dosing in rats for 7 days, salbutamol and triflusal, but not dimethadione or trazodone, significantly elevated FGF20 levels in the nigrostriatal tract." | 1.51 | Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats. ( Doherty, P; Duty, S; Fletcher, EJR; Jamieson, AD; Williams, G, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hadi, F | 1 |
| Agah, E | 1 |
| Tavanbakhsh, S | 1 |
| Mirsepassi, Z | 1 |
| Mousavi, SV | 1 |
| Talachi, N | 1 |
| Tafakhori, A | 1 |
| Aghamollaii, V | 1 |
| Fletcher, EJR | 1 |
| Jamieson, AD | 1 |
| Williams, G | 1 |
| Doherty, P | 1 |
| Duty, S | 1 |
| Werneck, AL | 1 |
| Rosso, AL | 1 |
| Vincent, MB | 1 |
| Mastrosimone, F | 1 |
| Colucci d'Amato, C | 1 |
| De Angelis, G | 1 |
| Iaccarino, C | 1 |
| Giordano, L | 1 |
| Marmo, E | 1 |
| Piccinin, GL | 1 |
| Piccirilli, M | 1 |
| Agostini, L | 1 |
2 trials available for trazodone and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Safety and efficacy of melatonin, clonazepam, and trazodone in patients with Parkinson's disease and sleep disorders: a randomized, double-blind trial.
Topics: Clonazepam; Double-Blind Method; Humans; Iran; Melatonin; Parkinson Disease; Sleep Wake Disorders; T | 2022 |
The use of an antagonist 5-HT2a/c for depression and motor function in Parkinson' disease.
Topics: Aged; Depression; Female; Humans; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Sc | 2009 |
3 other studies available for trazodone and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats.
Topics: Albuterol; Animals; Brain; Computer Simulation; Corpus Striatum; Dimethadione; Dopaminergic Neurons; | 2019 |
Personal experience with a combination of drugs in subjects with dopa resistant Parkinson's disease.
Topics: Amantadine; Amitriptyline; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Humans; Hyper | 1980 |
[Treatment of parkinson disease with the combination of L-dopa (plus carbidopa) and trazodone].
Topics: Aged; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson D | 1981 |